Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2020
Cantel Medical Corp. (CMD) reported its financial results for Q4 2020, showing net sales of $233.4M, a 2.5% decrease year-over-year. This decline was driven by an 18.0% organic sales drop, partially offset by 15.7% growth from acquisitions. GAAP EPS plummeted 125.5% to $(0.05), influenced by COVID impacts and restructuring costs. Non-GAAP EPS fell 62.6% to $0.24. The company generated $44.0M in cash from operations and ended the quarter with $277.9M in cash and $1,113.4M in debt. Daily sales rates improved to 80%-85% of pre-COVID levels, but full recovery timing remains uncertain.
- Dental revenue increased 59.0% due to the Hu-Friedy acquisition.
- Daily sales rates improved to 80%-85% of pre-COVID levels by the end of the quarter.
- The company paid down $75 million of its revolving credit facility.
- Net sales down 2.5% year-over-year.
- Organic sales decreased 18.0% due to COVID-related elective procedure reductions.
- GAAP EPS decreased 125.5% to $(0.05), impacted by higher amortization and restructuring costs.
LITTLE FALLS, N.J., Sept. 17, 2020 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its fourth quarter ended July 31, 2020.
Fourth quarter 2020 net sales were
Fourth quarter 2020 GAAP earnings per diluted share decreased
Fourth quarter 2020 Non-GAAP earnings per diluted share decreased
George Fotiades, Chief Executive Officer, stated, "We are pleased with our fourth quarter performance in the face of the impact of COVID on procedures in our Medical and Dental segments. We executed very well in managing operating expenses and working capital, and we were able to pay down
With the acquisition of Hu-Friedy, as well as the impact from COVID, the Company's balance sheet has changed from historical trends. The fourth quarter ended with cash of
Following the end of the fourth quarter, given its extremely strong cash position, the Company paid down
Fourth quarter financial results and key updates:
- Net cash provided by operating activities was
$44.0M - Life Sciences and Dialysis maintained revenue growth in line with previous expectations
- Dental revenue increased
59.0% , driven by the acquisition of Hu-Friedy, while organic revenue decreased20.6% due to deferred elective procedures, which was partially offset by strong performance in face masks, face shields, surface disinfectants and wipes - Medical revenue decreased
24.8% on an organic basis, with May revenue slightly increasing from April levels, and then strongly accelerating into June and July - Management instituted key cost and cash saving measures which included the following:
- Deployed workforce furloughs across manufacturing sites experiencing declines in demand, along with temporary furloughs and decreases in pay for administrative personnel
- Deferred all non-essential capital expenditures
- Cancelled all non-essential travel
- Reduced inventory in areas where demand has decreased, including aggressive material management to limit purchasing
- Suspended any cash dividend through at least October 31, 2021
- Suspended and reduced executive salaries and board of director compensation
While the impact of COVID on elective procedures was significant in Medical and Dental, daily sales rates improved over the course of the fourth quarter ahead of expectations. Estimated procedure volume continuously improved, following a trough in late April, to a level today in the
Conference Call Information:
The Company will hold a conference call to discuss the results for its fourth quarter ended July 31, 2020 later this morning, at 8:30 a.m. Eastern Daylight Time.
To participate in the conference call, dial 1-844-369-8770 (U.S. & Canada) or 1-862-298-0840 (International) approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, September 17, 2020 through 8:30 a.m. Eastern Daylight Time on October 16, 2020 by dialing 1-877-481-4010 (U.S. & Canada) or 1-919-882-2331 (International) and using conference ID #36688.
An audio webcast will be available via the Cantel website at www.cantelmedical.com. A replay of the presentation will be archived on the Cantel web site for those unable to listen live. In addition, the Company will provide a supplemental presentation to complement the conference call. The presentation can be accessed on Cantel's website in the Investor Relations section under presentations.
About Cantel Medical:
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, instruments and instrument reprocessing workflow systems serving the dental industry, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operate, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting the foregoing, words or phrases such as "expect," "anticipate," "look to," "goal," "project," "intend," "plan," "believe," "seek," "may," "could," "aspire" and variations of such words and similar expressions generally identify forward-looking statements. In addition, any statements that refer to predictions or projections of our future financial performance, anticipated growth, strategic objectives, performance drivers and trends in our businesses, the impacts and recovery from the COVID pandemic, and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions about future events, activities or developments and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict, including the impacts of the COVID-19 pandemic on our operations and financial results, general economic conditions, technological and market changes in the medical device industry, our ability to execute on our strategy, risks associated with operating our international business, including limited operating experience and market recognition in new international markets, changes in United States healthcare policy at both the state and federal level, product liability claims resulting from the use of products we sell and distribute, and risks related to our intellectual property and proprietary rights needed to maintain our competitive position. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter and by our Current Report on Form 8-K dated May 12, 2020. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CANTEL MEDICAL CORP. Condensed Consolidated Statements of Income (Unaudited) | |||||||||||||||
Three Months Ended | Twelve Months Ended | ||||||||||||||
July 31, | July 31, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Net sales | $ | 233,371 | $ | 239,476 | $ | 1,016,048 | $ | 918,155 | |||||||
Cost of sales | 133,094 | 128,823 | 576,675 | 490,701 | |||||||||||
Gross profit | 100,277 | 110,653 | 439,373 | 427,454 | |||||||||||
Expenses: | |||||||||||||||
Selling | 36,524 | 36,999 | 157,732 | 140,232 | |||||||||||
General and administrative | 48,091 | 49,856 | 197,562 | 172,383 | |||||||||||
Research and development | 8,419 | 8,965 | 32,372 | 31,320 | |||||||||||
Total operating expenses | 93,034 | 95,820 | 387,666 | 343,935 | |||||||||||
Income from operations | 7,243 | 14,833 | 51,707 | 83,519 | |||||||||||
Interest expense, net | 13,711 | 2,763 | 39,793 | 9,505 | |||||||||||
Other expense (income) | — | 8 | — | (1,305) | |||||||||||
(Loss) income before income taxes | (6,468) | 12,062 | 11,914 | 75,319 | |||||||||||
Income taxes | (4,210) | 3,237 | (5,119) | 20,277 | |||||||||||
Net (loss) income | $ | (2,258) | $ | 8,825 | $ | 17,033 | $ | 55,042 | |||||||
(Loss) earnings per common share - diluted | $ | (0.05) | $ | 0.21 | $ | 0.40 | $ | 1.32 | |||||||
Dividends declared per common share | $ | — | $ | 0.10 | $ | 0.105 | $ | 0.20 | |||||||
Weighted average shares - diluted | 42,140,273 | 41,823,577 | 42,309,216 | 41,757,116 | |||||||||||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
CANTEL MEDICAL CORP. Condensed Consolidated Balance Sheets (Unaudited) | |||||||
July 31, | July 31, | ||||||
Assets | |||||||
Cash and cash equivalents | $ | 277,871 | $ | 44,535 | |||
Accounts receivable, net | 148,419 | 146,910 | |||||
Inventories, net | 167,960 | 138,234 | |||||
Prepaid expenses and other current assets | 18,443 | 20,920 | |||||
Income taxes receivable | 32,762 | 1,197 | |||||
Total current assets | 645,455 | 351,796 | |||||
Property and equipment, net | 225,222 | 185,242 | |||||
Right-of-use assets, net | 48,684 | — | |||||
Intangible assets, net | 480,032 | 141,513 | |||||
Goodwill | 663,484 | 378,109 | |||||
Other long-term assets | 6,231 | 9,425 | |||||
Deferred income taxes | 4,787 | 4,281 | |||||
Total assets | $ | 2,073,895 | $ | 1,070,366 | |||
Liabilities and stockholders' equity | |||||||
Accounts payable | 42,008 | 39,450 | |||||
Compensation payable | 47,769 | 32,762 | |||||
Accrued expenses | 41,480 | 38,545 | |||||
Deferred revenue | 26,223 | 27,840 | |||||
Current portion of long-term debt | 7,375 | 10,000 | |||||
Income taxes payable | 4,373 | 2,803 | |||||
Current portion of lease liabilities | 10,268 | — | |||||
Total current liabilities | 179,496 | 151,400 | |||||
Long-term debt | 926,834 | 220,851 | |||||
Convertible debt | 124,835 | — | |||||
Deferred income taxes | 49,533 | 29,278 | |||||
Long-term lease liabilities | 40,679 | — | |||||
Other long-term liabilities | 20,778 | 7,300 | |||||
Total liabilities | 1,342,155 | 408,829 | |||||
Common stock | 4,681 | 4,636 | |||||
Additional paid-in capital | 273,040 | 204,795 | |||||
Retained earnings | 551,659 | 539,097 | |||||
Accumulated other comprehensive loss | (28,783) | (22,197) | |||||
Treasury stock | (68,857) | (64,794) | |||||
Total stockholders' equity | 731,740 | 661,537 | |||||
Total liabilities and stockholders' equity | $ | 2,073,895 | $ | 1,070,366 | |||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
CANTEL MEDICAL CORP. Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
Twelve Months Ended July 31, | |||||||
2020 | 2019 | ||||||
Cash flows from operating activities | |||||||
Net income | $ | 17,033 | $ | 55,042 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation | 30,441 | 21,510 | |||||
Amortization | 32,961 | 20,849 | |||||
Stock-based compensation expense | 12,076 | 15,562 | |||||
Deferred income taxes | 15,817 | (2,062) | |||||
Amortization of right-of-use assets | 10,292 | — | |||||
Amortization of debt issuance costs and debt discount | 3,810 | 594 | |||||
Inventory step-up amortization | 16,700 | 346 | |||||
Fair value adjustments to contingent consideration | (6,370) | — | |||||
Other non-cash items, net | 4,489 | (2,880) | |||||
Changes in assets and liabilities, net of effects of acquisitions/dispositions | (392) | (42,030) | |||||
Net cash provided by operating activities | 136,857 | 66,931 | |||||
Cash flows from investing activities | |||||||
Capital expenditures | (33,796) | (95,438) | |||||
Proceeds from sale of businesses, net | 2,287 | 3,053 | |||||
Acquisitions, net of cash acquired | (721,350) | (40,644) | |||||
Net cash used in investing activities | (752,859) | (133,029) | |||||
Cash flows from financing activities | |||||||
Proceeds from issuance of long-term debt | 400,000 | — | |||||
Repayments of long-term debt | (43,625) | (15,207) | |||||
Borrowings under revolving credit facility | 388,900 | 50,000 | |||||
Repayments under revolving credit facility | (32,900) | (7,000) | |||||
Proceeds from issuance of convertible debt | 168,000 | — | |||||
Dividends paid | (4,471) | (8,350) | |||||
Debt issuance costs | (17,081) | — | |||||
Finance lease payments | (399) | — | |||||
Contingent consideration payments | (1,691) | — | |||||
Purchases of treasury stock | (4,063) | (4,741) | |||||
Net cash provided by financing activities | 852,670 | 14,702 | |||||
Effect of exchange rate changes on cash and cash equivalents | (3,332) | 1,834 | |||||
Increase (decrease) in cash and cash equivalents | 233,336 | (49,562) | |||||
Cash and cash equivalents at beginning of period | 44,535 | 94,097 | |||||
Cash and cash equivalents at end of period | $ | 277,871 | $ | 44,535 | |||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
SUPPLEMENTARY INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
In evaluating our operating performance, we supplement the reporting of our financial information determined under generally accepted accounting principles in the United States ("GAAP") with certain non-GAAP financial measures including (i) non-GAAP net income, (ii) non-GAAP earnings per diluted share ("EPS"), (iii) earnings before interest, taxes, depreciation, amortization, loss on disposal of fixed assets, and stock-based compensation expense ("EBITDAS"), (iv) adjusted EBITDAS, (v) net debt and (vi) organic sales. These non-GAAP financial measures are indicators of our performance that are not required by, or presented in accordance with, GAAP. They are presented with the intent of providing greater transparency to financial information used by us in our financial analysis and operational decision-making. We believe that these non-GAAP measures provide meaningful information to assist investors, stockholders and other readers of our consolidated financial statements in making comparisons to our historical operating results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of our past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. The following are examples of the types of adjustments that are excluded: (i) amortization of purchased intangible assets, (ii) acquisition-related items, (iii) business optimization and restructuring-related charges, (iv) certain significant and discrete tax matters and (v) other significant items management deems irregular or non-operating in nature.
Amortization expense of purchased intangible assets is a non-cash expense related to intangibles that were primarily the result of business acquisitions. Our history of acquiring businesses has resulted in significant increases in amortization of intangible assets that reduce our net income. The removal of amortization from our overall operating performance helps in assessing our cash generated from operations including our return on invested capital, which we believe is an important analysis for measuring our ability to generate cash and invest in our continued growth.
Acquisition-related items consist of (i) fair value adjustments to contingent consideration and other contingent liabilities resulting from acquisitions, (ii) due diligence, integration, legal fees and other transaction costs associated with our acquisition program and (iii) acquisition accounting charges for the amortization of the initial fair value adjustments of acquired inventory and deferred revenue. The adjustments of contingent consideration and other contingent liabilities are periodic adjustments to record such amounts at fair value at each balance sheet date. Given the subjective nature of the assumptions used in the determination of fair value calculations, fair value adjustments may potentially cause significant earnings volatility that are not representative of our operating results. Similarly, due diligence, integration, legal and other acquisition costs associated with our acquisition program, including accounting charges relating to recording acquired inventory and deferred revenue at fair market value, can be significant and also adversely impact our effective tax rate as certain costs are often not tax-deductible. Since these acquisition-related items are irregular and often mask underlying operating performance, we exclude these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to past operating performance.
Restructuring-related and business optimization items consist of severance-related costs associated with workforce reductions and other restructuring-related activities. Such costs include (i) salary continuation, (ii) bonus payments, (iii) outplacement services, (iv) medical-related premium costs and (v) accelerated stock-compensation costs. Since these restructuring-related and business optimization items often mask underlying operating performance, we exclude these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to past operating performance.
Excess tax benefits and expenses resulting from stock compensation are recorded as an adjustment to income tax expense. The magnitude of the impact of excess tax benefits generated in the future, which may be favorable or unfavorable, are dependent upon our future grants of equity awards, our future share price on the date awards vest in relation to the fair value of awards on grant date and the exercise behavior of our stock award holders. Since these tax effects are largely unrelated to our results and unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS to arrive at our non-GAAP financial measures.
We are required under GAAP to separately account for the liability (debt) and equity (conversion option) components of our convertible debt issued in May 2020. Accordingly, we are required to recognize non-cash interest expense that is associated with the debt discount component recorded in equity. Since the amortization of the debt discount is a non-cash expense, we excluded its impact on net income and diluted EPS to arrive at our non-GAAP financial measures as we believe that the exclusion of the non-cash interest expense provides investors an enhanced view of our operational performance related to cash flow and liquidity.
During fiscal 2020, we recorded a discrete tax benefit related to a provision under the federal CARES Act, which allowed us to carryback taxable losses up to five years. As we believe that this item was not representative of our normal effective tax rate, we excluded its impact on net income and diluted EPS for fiscal 2020 to arrive at our non-GAAP financial measures.
During fiscal 2020, we completed the disposition of a dental product line, which resulted in a pre-tax loss of
During fiscal 2019, we recorded specific discrete tax items associated with our international operations that were unrelated to fiscal 2019. As we believe that these items were not representative of our normal effective tax rate, we excluded their impact on net income and diluted EPS for fiscal 2019 to arrive at our non-GAAP financial measures.
During fiscal 2019, we completed the disposition of our high purity water business in Canada, which resulted in a pre-tax gain of
During fiscal 2019, we recorded an adjustment to a minor litigation matter in our consolidated financial statements. Since we believe that these costs were irregular and mask our underlying operating performance, we made an adjustment to our net income and diluted EPS for fiscal 2019 to exclude such costs to arrive at our non-GAAP financial measures.
The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:
Three Months Ended July 31, | |||||||||||||||
(Unaudited) | 2020 | 2019 | |||||||||||||
Net (loss) income/Diluted EPS, as reported | $ | (2,258) | $ | (0.05) | $ | 8,825 | $ | 0.21 | |||||||
Intangible amortization, net of tax(1) | 7,613 | 0.18 | 4,093 | 0.10 | |||||||||||
Acquisition-related items, net of tax(2) | 2,028 | 0.05 | 5,453 | 0.13 | |||||||||||
Restructuring-related charges, net of tax(3) | 6,903 | 0.16 | 7,529 | 0.17 | |||||||||||
Convertible debt discount amortization, net of tax(4) | 1,036 | 0.02 | — | — | |||||||||||
Gain on disposition of business, net of tax(5) | — | — | (14) | — | |||||||||||
Loss on disposition of product line, net of tax(1) | (35) | — | — | — | |||||||||||
Excess tax benefits(6) | — | — | (21) | — | |||||||||||
Tax matters(6) | (5,291) | (0.12) | 666 | 0.02 | |||||||||||
Non-GAAP net income/Non-GAAP diluted EPS | $ | 9,996 | $ | 0.24 | $ | 26,531 | $ | 0.63 | |||||||
________________________________________________ | |
(1) | Amounts were recorded in general and administrative expenses. |
(2) | In fiscal 2020, pre-tax acquisition-related items of |
(3) | In fiscal 2020, pre-tax restructuring-related items of |
(4) | Amounts were recorded in interest expense, net. |
(5) | Amounts were recorded in other income. |
(6) | Amounts were recorded in income taxes. |
(dollar amounts in thousands except share and per share data or as otherwise specified) | |
The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:
Twelve Months Ended July 31, | |||||||||||||||
(Unaudited) | 2020 | 2019 | |||||||||||||
Net income/Diluted EPS, as reported | $ | 17,033 | $ | 0.40 | $ | 55,042 | $ | 1.32 | |||||||
Intangible amortization, net of tax(1) | 24,944 | 0.59 | 16,021 | 0.38 | |||||||||||
Acquisition-related items, net of tax(2) | 20,133 | 0.48 | 9,689 | 0.23 | |||||||||||
Restructuring-related charges, net of tax(3) | 16,626 | 0.39 | 18,015 | 0.43 | |||||||||||
Convertible debt discount amortization, net of tax(4) | 1,036 | 0.02 | — | — | |||||||||||
Litigation matters, net of tax(1) | — | — | 134 | — | |||||||||||
Gain on disposition of business, net of tax(5) | — | — | (943) | (0.02) | |||||||||||
Loss on disposition of product line, net of tax(1) | 95 | — | — | — | |||||||||||
Excess tax benefits(6) | 559 | 0.01 | (584) | (0.01) | |||||||||||
Tax matters(6) | (10,574) | (0.24) | 1,625 | 0.04 | |||||||||||
Non-GAAP net income/Non-GAAP diluted EPS | $ | 69,852 | $ | 1.65 | $ | 98,999 | $ | 2.37 | |||||||
________________________________________________ | |
(1) | Amounts were recorded in general and administrative expenses. |
(2) | In fiscal 2020, pre-tax acquisition-related items of |
(3) | In fiscal 2020, pre-tax restructuring-related items of |
(4) | Amounts were recorded in interest expense, net. |
(5) | Amounts were recorded in other income. |
(6) | Amounts were recorded in income taxes. |
(dollar amounts in thousands except share and per share data or as otherwise specified) | |
Reconciliation of Net Income to EBITDAS and Adjusted EBITDAS
We believe EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment have on net income. In particular, acquisitions have historically resulted in significant increases in amortization of purchased intangible assets that reduce net income. Additionally, we regard EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and is a complement to operating income, net income and other GAAP financial performance measures.
We define adjusted EBITDAS as EBITDAS excluding the same non-GAAP adjustments to net income discussed above. We use adjusted EBITDAS when evaluating operating performance because we believe the exclusion of such adjustments, of which a significant portion are non-cash items, is necessary to provide the most accurate measure of on-going core operating results and to evaluate comparative results period over period.
The reconciliations of net income to EBITDAS and adjusted EBITDAS were calculated as follows:
Three Months Ended July 31, | Twelve Months Ended July 31, | ||||||||||||||
(Unaudited) | 2020 | 2019 | 2020 | 2019 | |||||||||||
Net (loss) income, as reported | $ | (2,258) | $ | 8,825 | $ | 17,033 | $ | 55,042 | |||||||
Interest expense, net | 13,711 | 2,763 | 39,793 | 9,505 | |||||||||||
Income taxes | (4,210) | 3,237 | (5,119) | 20,277 | |||||||||||
Depreciation | 8,336 | 6,055 | 30,441 | 21,510 | |||||||||||
Amortization | 9,009 | 5,341 | 32,961 | 20,849 | |||||||||||
Loss on disposal of fixed assets | 102 | 224 | 1,399 | 1,592 | |||||||||||
Stock-based compensation expense | 3,233 | 3,677 | 12,076 | 15,562 | |||||||||||
EBITDAS | 27,923 | 30,122 | 128,584 | 144,337 | |||||||||||
Acquisition-related items(1) | 1,190 | 7,332 | 25,787 | 13,129 | |||||||||||
Restructuring-related charges(1) | 8,801 | 9,653 | 22,204 | 18,524 | |||||||||||
Litigation matters | — | — | — | 163 | |||||||||||
Loss on disposition of product line | (43) | — | 127 | — | |||||||||||
Gain on disposition of business | — | 8 | — | (1,305) | |||||||||||
Adjusted EBITDAS | $ | 37,871 | $ | 47,115 | $ | 176,702 | $ | 174,848 | |||||||
________________________________________________ | |
(1) | Excludes stock-based compensation expense. |
(dollar amounts in thousands except share and per share data or as otherwise specified) | |
Net Debt
We define net debt as long-term debt (bank debt excluding unamortized debt issuance costs) plus convertible debt (excluding unamortized debt issuance costs and unamortized discount), less cash and cash equivalents. We believe that the presentation of net debt provides useful information to investors because we review net debt as part of our management of our overall liquidity, financial flexibility, capital structure and leverage.
(Unaudited) | July 31, 2020 | July 31, 2019 | |||||
Long-term debt (excluding debt issuance costs) | $ | 945,375 | $ | 233,000 | |||
Convertible debt (excluding debt issuance costs and discount) | 168,000 | — | |||||
Less cash and cash equivalents | (277,871) | (44,535) | |||||
Net debt | $ | 835,504 | $ | 188,465 | |||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
Reconciliation of Net Sales Growth to Organic Sales Growth
We define organic sales as net sales less (i) the impact of foreign currency translation, (ii) net sales related to acquired businesses during the first twelve months of ownership and (iii) dispositions during the periods being compared. We believe that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior periods. We exclude the effect of foreign currency translation from organic sales because foreign currency translation is not under management's control, is subject to volatility and can obscure underlying business trends. We exclude the effect of acquisitions and dispositions because the nature, size, and number of acquisitions and dispositions can vary dramatically from period to period and can obscure underlying business trends and make comparisons of financial performance difficult.
For the three months ended July 31, 2020, the reconciliation of net sales growth to organic sales growth for total net sales and net sales of our four reportable segments were calculated as follows:
(Unaudited) | Net Sales | Medical | Life Sciences | Dental | Dialysis | ||||||||||
Net sales growth | (2.5) | % | (25.0) | % | 0.7 | % | 59.0 | % | 0.2 | % | |||||
Impact due to foreign currency translation | (0.2) | % | (0.2) | % | (0.2) | % | — | % | (0.2) | % | |||||
Sales related to acquisitions | 15.7 | % | — | % | — | % | 79.6 | % | — | % | |||||
Organic sales growth | (18.0) | % | (24.8) | % | 0.9 | % | (20.6) | % | 0.4 | % | |||||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
For the twelve months ended July 31, 2020, the reconciliation of net sales growth to organic sales growth for total net sales and net sales of our four reportable segments were calculated as follows:
(Unaudited) | Net Sales | Medical | Life Sciences | Dental | Dialysis | ||||||||||
Net sales growth | 10.7 | % | (10.6) | % | 0.2 | % | 92.3 | % | (5.3) | % | |||||
Impact due to foreign currency translation | (0.4) | % | (0.6) | % | (0.1) | % | — | % | (0.1) | % | |||||
Sales related to acquisitions/dispositions | 17.1 | % | — | % | (1.7) | % | 95.5 | % | — | % | |||||
Organic sales growth | (6.0) | % | (10.0) | % | 2.0 | % | (3.2) | % | (5.2) | % | |||||
(dollar amounts in thousands except share and per share data or as otherwise specified) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/cantel-medical-reports-financial-results-for-its-fourth-quarter-fiscal-year-2020-301132774.html
SOURCE Cantel Medical Corp.
FAQ
What were Cantel Medical Corp's earnings in Q4 2020?
How did COVID-19 affect Cantel Medical Corp's sales?
What was the revenue trend for Cantel Medical Corp in Q4 2020?
What is the future outlook for Cantel Medical Corp?
